Skip to Content
Biotechnology

A drug that cools the body’s reaction to Covid-19 appears to save lives

US Dept. of Defense

In an advance toward conquering covid-19, doctors in Michigan say an antibody drug may sharply cut the chance patients on a ventilator will die.

The problem: The pandemic viral disease is infecting millions, and for those who end up on a ventilator in an ICU, the odds are grim. More than half are dying.

The drug: Doctors at the University of Michigan set out to control the haywire immune reaction that pushes some covid-19 patients into a death spiral. To do it, they gave 78 patients on ventilators the drug tocilizumab, which blocks IL-6, a molecule in the body that sets off a reaction to an infection. (The drug is sold by Roche under the trade name Actemra.)

The result: The doctors say in a preprint that patients who got the drug were 45% less likely to die than those who didn’t. But there’s a big caveat, which is that the doctors knew which patients got the drug and which didn’t. Their picks for the drug-taking group could have been biased— people more likely to improve anyway, for example—so further studies are needed.

Emerging cocktail: In late May, Roche said it would start a trial to combine its IL-6 blocker with remdesivir, an antiviral drug with modest benefits that got emergency approval in the US for treating covid-19. That drug is meant to block the virus from replicating.

By combining the two drugs, doctors may be closing in on a cocktail able to cut the death rate from the virus, a step that would help society return to normal.

Deep Dive

Biotechnology

The first babies conceived with a sperm-injecting robot have been born

Meet the startups trying to engineer a desktop fertility machine.

Doctors have performed brain surgery on a fetus in one of the first operations of its kind

A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.

A brain implant changed her life. Then it was removed against her will.

Her case highlights why we need to enshrine neuro rights in law.

The FDA just approved rub-on gene therapy that helps “butterfly” children

Biotech companies are getting creative with how they deliver DNA fixes into people's bodies.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.